Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction Study of Upadacitinib in Moderately to Severely Active Crohn's Disease After Biologic Failure
2017-001226-18Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Upadacitinib induction with Placebo induction (2 arms). Primary endpoint: Co-primary endpoints. Started Nov 2017; status: completed.
02
Drugs
upadacitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2017-001226-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001226-18.